1
|
Ong K, Bald P, Dryhurst D, Ahmed S, Yusuf GT, Lunawat R, Sriprasad S, Thapa G, Tirnoveanu A, Webb R, Rahman E. The design and validation of a low-cost trans perineal (TP) prostate biopsy simulator for training: improving trainees' confidence and cognitive targeting skills. World J Urol 2023:10.1007/s00345-023-04387-y. [PMID: 37129680 PMCID: PMC10153043 DOI: 10.1007/s00345-023-04387-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Accepted: 03/27/2023] [Indexed: 05/03/2023] Open
Abstract
PURPOSE The aim of this research was to create a novel and low-cost TP prostate biopsy simulator that has face, content and construct validity with high educational value. METHODS This research developed a trans perineal prostate (TP) biopsy simulator using 3D-printed moulds and tissue-mimicking materials. Important regions (anterior, mid, and posterior zones) were coded with different colours. Ultrasound visible abnormal lesions were embedded in the prostate phantom. Expert and novice participants in TP biopsies were recruited. Essential skills were identified through the consensus of six experts. These skills were assessed through tasks performed by participants. This included the accuracy and timing of systematic and target biopsies. Immediate feedback was determined by the colour of the biopsy cores taken. A survey was distributed to evaluate its realism and educational value. RESULTS The material cost of one simulator was £7.50. This simulator was proven to have face, content, and construct validity. There was a significant difference (p = 0.02) in the accuracy of systematic biopsies between both experts and novices. Significant difference was also observed (p = 0.01), in accurately identifying target lesion on ultrasound between both groups. Participants rated the overall realism of the simulator 4.57/5 (range 3-5). 100% of the experts agreed that introducing this simulator to training will be beneficial. 85.7% of the participants strongly agree that the simulator improved their confidence in TP biopsies. CONCLUSION There is value in integrating this proof-of-concept TP prostate biopsy simulator into training. It has highly rated educational value and has face, content, and construct validity.
Collapse
Affiliation(s)
- Kelly Ong
- Institute of Medical Sciences, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Rowan Williams Court, 30 Pembroke Court, Chatham Maritime, Kent, ME4 4UF, UK
- Princess Royal University Hospital, Farnborough Common, Bromley, Kent, BR6 8ND, UK
| | - Philip Bald
- Institute of Mechanical Engineers (IMechE), London, UK
| | - David Dryhurst
- Princess Royal University Hospital, Farnborough Common, Bromley, Kent, BR6 8ND, UK
| | - Saif Ahmed
- Institute of Medical Sciences, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Rowan Williams Court, 30 Pembroke Court, Chatham Maritime, Kent, ME4 4UF, UK
| | - Gibran Tim Yusuf
- Princess Royal University Hospital, Farnborough Common, Bromley, Kent, BR6 8ND, UK
| | - Rahul Lunawat
- Princess Royal University Hospital, Farnborough Common, Bromley, Kent, BR6 8ND, UK
| | - Seshadri Sriprasad
- Institute of Medical Sciences, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Rowan Williams Court, 30 Pembroke Court, Chatham Maritime, Kent, ME4 4UF, UK
| | - Gauri Thapa
- Institute of Medical Sciences, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Rowan Williams Court, 30 Pembroke Court, Chatham Maritime, Kent, ME4 4UF, UK
| | - Alice Tirnoveanu
- Institute of Medical Sciences, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Rowan Williams Court, 30 Pembroke Court, Chatham Maritime, Kent, ME4 4UF, UK
| | - Richard Webb
- Institute of Medical Sciences, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Rowan Williams Court, 30 Pembroke Court, Chatham Maritime, Kent, ME4 4UF, UK
| | - Eqram Rahman
- Institute of Medical Sciences, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Rowan Williams Court, 30 Pembroke Court, Chatham Maritime, Kent, ME4 4UF, UK.
| |
Collapse
|
2
|
Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clin Cancer Inform 2022; 6:e2200016. [PMID: 36179281 DOI: 10.1200/cci.22.00016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE There is ongoing clinical need to improve estimates of disease outcome in prostate cancer. Machine learning (ML) approaches to pathologic diagnosis and prognosis are a promising and increasingly used strategy. In this study, we use an ML algorithm for prediction of adverse outcomes at radical prostatectomy (RP) using whole-slide images (WSIs) of prostate biopsies with Grade Group (GG) 2 or 3 disease. METHODS We performed a retrospective review of prostate biopsies collected at our institution which had corresponding RP, GG 2 or 3 disease one or more cores, and no biopsies with higher than GG 3 disease. A hematoxylin and eosin-stained core needle biopsy from each site with GG 2 or 3 disease was scanned and used as the sole input for the algorithm. The ML pipeline had three phases: image preprocessing, feature extraction, and adverse outcome prediction. First, patches were extracted from each biopsy scan. Subsequently, the pre-trained Visual Geometry Group-16 convolutional neural network was used for feature extraction. A representative feature vector was then used as input to an Extreme Gradient Boosting classifier for predicting the binary adverse outcome. We subsequently assessed patient clinical risk using CAPRA score for comparison with the ML pipeline results. RESULTS The data set included 361 WSIs from 107 patients (56 with adverse pathology at RP). The area under the receiver operating characteristic curves for the ML classification were 0.72 (95% CI, 0.62 to 0.81), 0.65 (95% CI, 0.53 to 0.79) and 0.89 (95% CI, 0.79 to 1.00) for the entire cohort, and GG 2 and GG 3 patients, respectively, similar to the performance of the CAPRA clinical risk assessment. CONCLUSION We provide evidence for the potential of ML algorithms to use WSIs of needle core prostate biopsies to estimate clinically relevant prostate cancer outcomes.
Collapse
Affiliation(s)
| | - Tal Zeevi
- Yale School of Medicine, New Haven, CT
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Bommelaere T, Villers A, Puech P, Ploussard G, Labreuche J, Drumez E, Leroy X, Olivier J. Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy. EUR UROL SUPPL 2022; 41:24-34. [PMID: 35813259 PMCID: PMC9257652 DOI: 10.1016/j.euros.2022.04.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/14/2022] [Indexed: 12/03/2022] Open
Abstract
Background The risk of prostate cancer metastatic is correlated with its volume and grade. These parameters are now best estimated preoperatively with magnetic resonance imaging (MRI) and MRI-guided biopsy. Objective To estimate the risk of metastatic recurrence after radical prostatectomy (RP) in our model versus conventional clinical European Association of Urology (EAU) classification. The secondary objective is biochemical recurrence (BCR). Design, setting, and participants A retrospective study was conducted of a cohort of 713 patients having undergone MRI-guided biopsies and RP between 2009 and 2018. The preoperative variables included prostate-specific antigen, cT stage, tumor volume (TV) based on the lesion’s largest diameter at MRI, percentage of Gleason pattern 4/5 (%GP4/5) at MRI-guided biopsy, and volume of GP4/5 (VolGP4/5) calculated as TV × %GP4/5. Outcome measurements and statistical analysis The variables’ ability to predict recurrence was determined in univariable and multivariable Fine-and-Gray models, according to the Akaike information criterion (AIC) and Harrell’s C-index. Results and limitations Overall, 176 (25%), 430 (60%), and 107 (15%) patients had low, intermediate, and high-risk disease, respectively, according to the EAU classification. During a median follow-up period of 57 mo, metastatic recurrence was observed in 48 patients with a 5-yr probability of 5.6% (95% confidence interval [CI] 3.9–7.7). VolGP4/5 (categories: <0.5, 0.5–1.0, 1.01–3.2, and >3.2 ml) was the parameter with the lowest AIC and the highest C-index for metastatic recurrence of 0.82 (95% CI 0.76–0.88), and for BCR it was 0.73 (95% CI 0.68–0.78). In a multivariable model that included %GP4/5 and TV, C-index values were 0.86 (95% CI 0.79–0.91) for metastatic recurrence and 0.77 (0.72–0.82) for BCR. The same results for EAU classification were 0.74 (0.67–0.80) and 0.67 (0.63–0.72), respectively. Limitations are related to short follow-up and expertise of radiologists and urologists. Conclusions We developed a preoperative risk tool integrating the VolGP4/5 based on MRI and MRI-guided biopsies to predict metastatic recurrence after RP. Our model showed higher accuracy than conventional clinical risk models. These findings might enable physicians to provide more personalized patient care. Patient summary Aggressiveness of prostate cancer evaluated before treatment by incorporating magnetic resonance imaging (MRI) and MRI-guided biopsy results gives a better estimate of the risk of metastatic recurrence than previous parameters not based on MRI.
Collapse
Affiliation(s)
| | - Arnauld Villers
- Department of Urology, University of Lille, Lille, France
- UMR8161/CNRS-Institut de Biologie de Lille, Lille, France
| | - Philippe Puech
- Department of Radiology, University of Lille, 59000 Lille, France
| | | | - Julien Labreuche
- Department of Biostatistics, CHU Lille, Lille, France
- ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, CHU Lille, University of Lille, Lille, France
| | - Elodie Drumez
- Department of Biostatistics, CHU Lille, Lille, France
- ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, CHU Lille, University of Lille, Lille, France
| | - Xavier Leroy
- Department of Histopathology, University of Lille, Lille, France
| | - Jonathan Olivier
- Department of Urology, University of Lille, Lille, France
- UMR8161/CNRS-Institut de Biologie de Lille, Lille, France
- Corresponding author. Department of Urology, Hôpital Huriez, Lille University, F-59000 Lille, France. Tel. + 33 320 444 235.
| |
Collapse
|
4
|
Kornienko K, Siegel F, Borkowetz A, Hoffmann MA, Drerup M, Lieb V, Bruendl J, Höfner T, Cash H, von Hardenberg J, Westhoff N. Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study. Prostate Cancer Prostatic Dis 2022; 25:109-116. [PMID: 34916584 PMCID: PMC9018419 DOI: 10.1038/s41391-021-00478-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 11/18/2021] [Accepted: 11/23/2021] [Indexed: 02/04/2023]
Abstract
BACKGROUND Although multiparametric magnetic resonance imaging (mpMRI) is recommended for primary risk stratification and follow-up in Active Surveillance (AS), it is not part of common AS inclusion criteria. The objective was to compare AS eligibility by systematic biopsy (SB) and combined MRI-targeted (MRI-TB) and SB within real-world data using current AS guidelines. METHODS A retrospective multicenter study was conducted by a German prostate cancer (PCa) working group representing six tertiary referral centers and one outpatient practice. Men with PCa and at least one MRI-visible lesion according to Prostate Imaging Reporting and Data System (PI-RADS) v2 were included. Twenty different AS inclusion criteria of international guidelines were applied to calculate AS eligibility using either a SB or a combined MRI-TB and SB. Reasons for AS exclusion were assessed. RESULTS Of 1941 patients with PCa, per guideline, 583-1112 patients with PCa in both MRI-TB and SB were available for analysis. Using SB, a median of 22.1% (range 6.4-72.4%) were eligible for AS. Using the combined approach, a median of 15% (range 1.7-68.3%) were eligible for AS. Addition of MRI-TB led to a 32.1% reduction of suitable patients. Besides Gleason Score upgrading, the maximum number of positive cores were the most frequent exclusion criterion. Variability in MRI and biopsy protocols potentially limit the results. CONCLUSIONS Only a moderate number of patients with PCa can be monitored by AS to defer active treatment using current guidelines for inclusion in a real-world setting. By an additional MRI-TB, this number is markedly reduced. These results underline the need for a contemporary adjustment of AS inclusion criteria.
Collapse
Affiliation(s)
- Kira Kornienko
- grid.6363.00000 0001 2218 4662Department of Urology, Charité University Medicine Berlin, Berlin, Germany ,grid.7497.d0000 0004 0492 0584Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Fabian Siegel
- grid.7700.00000 0001 2190 4373Department of Biomedical Informatics at the Center for Preventive Medicine and Digital Health, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany ,grid.7700.00000 0001 2190 4373Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Angelika Borkowetz
- grid.412282.f0000 0001 1091 2917Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Manuela A. Hoffmann
- Department of Occupational Health and Safety, Federal Ministry of Defense, Bonn, Germany ,grid.410607.4Department of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Martin Drerup
- grid.21604.310000 0004 0523 5263Department of Urology, Paracelsus Medical University, Salzburg, Austria
| | - Verena Lieb
- grid.5330.50000 0001 2107 3311Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
| | - Johannes Bruendl
- grid.7727.50000 0001 2190 5763Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
| | - Thomas Höfner
- grid.410607.4Department of Urology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Hannes Cash
- PROURO Berlin, Berlin, Germany ,grid.5807.a0000 0001 1018 4307Department of Urology, University Magdeburg, Magdeburg, Germany
| | - Jost von Hardenberg
- grid.7700.00000 0001 2190 4373Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Niklas Westhoff
- grid.7700.00000 0001 2190 4373Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | | |
Collapse
|
5
|
Lavi A, Yudkevich B, Pechansky S, Tzemach S, Hussein A, Bshara I, Halstuch D, Zelichenko G, Gross M, Cohen M. Implications of a Novel Biopsy Downloading System on Prostate Cancer Detection Rate, Surveillance and Focal Therapy - A Prospective Study. Urology 2021; 160:154-160. [PMID: 34780845 DOI: 10.1016/j.urology.2021.09.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 08/21/2021] [Accepted: 09/06/2021] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To examine the SmartBx, a novel biopsy downloading system, allowing downloading of biopsy cores with maximal core preservation as prostate biopsy sampling lacks preservation of core configuration & orientation. METHODS We prospectively collected cores from TRUS biopsy patients. Half were collected using the SmartBx & half using standard downloading. We measured length of the first ∼3200 cores through various pathology steps and within core cancer length in 160 SmartBx cores. We compared core length, yield (% of core available for final analysis/ original core on needle) and cancer detection rate between SmartBx and standard cores. T-test or chi-square were used for analysis. RESULTS 6014 cores were collected from 429 patients. Core length (12.3mm vs. 10mm; P<.01) and core yield (77.5% vs. 62.2%; P<.01) were significantly higher using the SmartBx compared to standard method, respectively. Cancer detection rate was significantly higher using the SmartBx for patients with PSA<10 (10.1% vs. 7.96%; n=2080 & n=2073, respectively; P<.016). Other subgroups showed non-significant higher detection rate for SmartBx cores. We noticed higher detection rate of clinically significant prostate cancer. Within core cancer length in 160 SmartBx cores was significantly lower compared to standard positive whole cores (4.45mm vs. 10.9mm; P<.001). Assuming cancer site a perfect sphere, disease volume was 11-fold lower for within core compared to entire core (46.1mm vs. 679.9mm; P<.0001). CONCLUSIONS SmartBx results in significant higher core length, yield and cancer detection rate. Precise localization of within core tumor foci allows significant reduction in tumor volume.
Collapse
Affiliation(s)
- Arnon Lavi
- Department of Urology, Haamek Medical Center, Afula, Israel.
| | - Boris Yudkevich
- Department of Urology, Haamek Medical Center, Afula, Israel; Urology Service, Yoseftal Medical Center, Eilat, Israel
| | | | - Sharon Tzemach
- Department of Urology, Haamek Medical Center, Afula, Israel
| | - Anan Hussein
- Department of Urology, Haamek Medical Center, Afula, Israel
| | - Ibrahim Bshara
- Department of Urology, Haamek Medical Center, Afula, Israel
| | - Daniel Halstuch
- Department of Urology, Rabin Medical Center, Petah-Tikva, Israel
| | | | - Michael Gross
- Department of Urology, Haamek Medical Center, Afula, Israel
| | - Michael Cohen
- Department of Urology, Haamek Medical Center, Afula, Israel
| |
Collapse
|
6
|
Combined Systematic and MRI-US Fusion Prostate Biopsy Has the Highest Grading Accuracy When Compared to Final Pathology. ACTA ACUST UNITED AC 2021; 57:medicina57060519. [PMID: 34067302 PMCID: PMC8224801 DOI: 10.3390/medicina57060519] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 05/06/2021] [Accepted: 05/19/2021] [Indexed: 02/05/2023]
Abstract
Background and objectives: Systematic prostate biopsy (SB) has a low Gleason group (GG) accuracy when compared to final pathology. This may negatively impact the inclusion of patients into specific risk groups and treatment choice. The aim of our study was to assess the GG accuracy of magnetic resonance imaging-ultrasound (MRI-US) fusion prostate biopsy. Materials and Methods: Of a cohort of minimally invasive radical prostatectomy (RP), we selected all patients who were diagnosed with prostate cancer (PCa) via MRI-US fusion biopsy (n = 115). Results: Combined biopsy had the highest rate for GG concordance (61.7% vs. 60.4% for SB vs. 45.3% for MRI-US fusion biopsy) and the lowest for upgrading (20.9% vs. 24.5% for SB vs. 34.9% for MRI-US fusion biopsy), p < 0.0001. No clinical data were predictive for upgrading or downgrading at final pathology. Locally advanced PCa was associated with a high Prostate Imaging-Reporting and Data System (PIRADS) score (p = 0.0014) and higher percentages of positive biopsy cores (PBC)/targeted (p = 0.0002) and PBC/total (p = 0.01). Positive surgical margins were correlated with higher percentages of PBC/systematic (p = 0.003) and PBC/total (p = 0.009). Conclusions: Pre-biopsy prostate MRI improves GG concordance between biopsy and RP. Combined biopsy provides the highest grading accuracy when compared to final pathology. Targeted and systematic biopsy data are predictive for adverse pathologic outcomes.
Collapse
|
7
|
Paulson N, Vollmer RT, Humphrey PA, Sprenkle PC, Onofrey J, Huber S, Amirkhiz K, Levi AW. Extent of High-Grade Prostatic Adenocarcinoma in Multiparametric Magnetic Resonance Imaging-Targeted Biopsy Enhances Prediction of Pathologic Stage. Arch Pathol Lab Med 2021; 146:201-204. [PMID: 34015819 DOI: 10.5858/arpa.2020-0568-oa] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2021] [Indexed: 11/06/2022]
Abstract
CONTEXT.— Multiparametric magnetic resonance imaging (mpMRI) of prostate with targeted biopsy has enhanced detection of high-grade prostatic adenocarcinoma (HG PCa). However, utility of amount of HG PCa (Gleason pattern 4/5) in mpMRI-targeted biopsies versus standard 12-core biopsies in predicting adverse outcomes on radical prostatectomy (RP) is unknown. OBJECTIVE.— To examine the utility of amount of HG PCa in mpMRI-targeted biopsies versus standard 12-core biopsies in predicting adverse RP outcomes. DESIGN.— We performed a retrospective review of prostate biopsies, which had corresponding RP, 1 or more mpMRI-targeted biopsy, and grade group 2 disease or higher. For the 169 cases identified, total millimeters of carcinoma and HG PCa, and longest length HG PCa in a single core were recorded for 12-core biopsies and each set of mpMRI-targeted biopsies. For RP specimens, Gleason grade, extraprostatic extension, seminal vesicle involvement, and lymph node metastasis were recorded. The main outcome studied was prostate-confined disease at RP. A logistic regression model was used to test which pre-RP variables related to this outcome. RESULTS.— Univariate analysis showed significant associations with adverse RP outcomes in 5 of 8 quantifiable variables; longest millimeter HG PCa in a single 12-core biopsy, highest grade group in any core, and total millimeter HG in mpMRI-targeted biopsies showed no statistical association (P = .54, P = .13, and P = .55, respectively). In multivariate analysis, total millimeter carcinoma in all cores, highest GrGrp in any core, and longest millimeter HG PCa in a single mpMRI-targeted core provided additional predictive value (P < .001, P = .004, and P = .03, respectively). CONCLUSIONS.— Quantitation of HG PCa in mpMRI-targeted biopsies provides additional value over 12-core biopsies alone in predicting nonorgan confined prostate cancer at RP. Linear millimeters of HG PCa in mpMRI-targeted biopsies is a significant parameter associated with higher pathologic stage and could be of value in risk models.
Collapse
Affiliation(s)
- Nathan Paulson
- From the Department of Pathology (Paulson, Humphrey, Levi), Yale University School of Medicine, New Haven, Connecticut
| | - Robin T Vollmer
- the Department of Pathology, Veterans Affairs and Duke University Medical Centers, Durham, North Carolina (Vollmer)
| | - Peter A Humphrey
- From the Department of Pathology (Paulson, Humphrey, Levi), Yale University School of Medicine, New Haven, Connecticut
| | - Preston C Sprenkle
- Department of Urology (Sprenkle, Onofrey, Amirkhiz), Yale University School of Medicine, New Haven, Connecticut
| | - John Onofrey
- Department of Urology (Sprenkle, Onofrey, Amirkhiz), Yale University School of Medicine, New Haven, Connecticut.,Radiology & Biomedical Imaging (Onofrey, Huber), Yale University School of Medicine, New Haven, Connecticut
| | - Steffen Huber
- Radiology & Biomedical Imaging (Onofrey, Huber), Yale University School of Medicine, New Haven, Connecticut
| | - Kamyar Amirkhiz
- Department of Urology (Sprenkle, Onofrey, Amirkhiz), Yale University School of Medicine, New Haven, Connecticut
| | - Angelique W Levi
- From the Department of Pathology (Paulson, Humphrey, Levi), Yale University School of Medicine, New Haven, Connecticut
| |
Collapse
|
8
|
van Son MJ, Peters M, Reddy D, Shah TT, Hosking-Jervis F, Robinson S, Lagendijk JJW, Mangar S, Dudderidge T, McCracken S, Hindley RG, Emara A, Nigam R, Persad R, Virdi J, Lewi H, Moore C, Orczyk C, Emberton M, Arya M, Ahmed HU, van der Voort van Zyp JRN, Winkler M, Falconer A. Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer Prostatic Dis 2021; 24:1120-1128. [PMID: 33934114 DOI: 10.1038/s41391-021-00369-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2020] [Revised: 03/14/2021] [Accepted: 04/15/2021] [Indexed: 11/09/2022]
Abstract
BACKGROUND For localised prostate cancer, focal therapy offers an organ-sparing alternative to radical treatments (radiotherapy or prostatectomy). Currently, there is no randomised comparative effectiveness data evaluating cancer control of both strategies. METHODS Following the eligibility criteria PSA < 20 ng/mL, Gleason score ≤ 7 and T-stage ≤ T2c, we included 830 radical (440 radiotherapy, 390 prostatectomy) and 530 focal therapy (cryotherapy, high-intensity focused ultrasound or high-dose-rate brachytherapy) patients treated between 2005 and 2018 from multicentre registries in the Netherlands and the UK. A propensity score weighted (PSW) analysis was performed to compare failure-free survival (FFS), with failure defined as salvage treatment, metastatic disease, systemic treatment (androgen deprivation therapy or chemotherapy), or progression to watchful waiting. The secondary outcome was overall survival (OS). Median (IQR) follow-up in each cohort was 55 (28-83) and 62 (42-83) months, respectively. RESULTS At baseline, radical patients had higher PSA (10.3 versus 7.9) and higher-grade disease (31% ISUP 3 versus 11%) compared to focal patients. After PSW, all covariates were balanced (SMD < 0.1). 6-year weighted FFS was higher after radical therapy (80.3%, 95% CI 73.9-87.3) than after focal therapy (72.8%, 95% CI 66.8-79.8) although not statistically significant (p = 0.1). 6-year weighted OS was significantly lower after radical therapy (93.4%, 95% CI 90.1-95.2 versus 97.5%, 95% CI 94-99.9; p = 0.02). When compared in a three-way analysis, focal and LRP patients had a higher risk of treatment failure than EBRT patients (p < 0.001), but EBRT patients had a higher risk of mortality than focal patients (p = 0.008). CONCLUSIONS Within the limitations of a cohort-based analysis in which residual confounders are likely to exist, we found no clinically relevant difference in cancer control conferred by focal therapy compared to radical therapy at 6 years.
Collapse
Affiliation(s)
- Marieke J van Son
- Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. .,Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK. .,Department of Radiotherapy, University Medical Centre Utrecht, Utrecht, The Netherlands.
| | - Max Peters
- Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.,Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK
| | - Deepika Reddy
- Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
| | - Taimur T Shah
- Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.,Department of Urology, Sunderland Royal Hospital, City Hospital Foundation Trust, Sunderland, UK
| | - Feargus Hosking-Jervis
- Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
| | - Stephen Robinson
- Division of Clinical Oncology, Department of Radiotherapy, Charing Cross Hospital, Imperial College London Healthcare NHS Trust, London, UK
| | - Jan J W Lagendijk
- Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK
| | - Stephen Mangar
- Imperial Urology, Imperial College Healthcare NHS Trust, London, UK
| | - Tim Dudderidge
- Department of Urology, University Hospital Southampton NHS Trust, Southampton, UK
| | - Stuart McCracken
- Department of Urology, Sunderland Royal Hospital, City Hospital Foundation Trust, Sunderland, UK
| | - Richard G Hindley
- Department of Urology, Hampshire Hospitals & Ain Shams University Hospitals, Basingstoke, UK
| | - Amr Emara
- Department of Urology, Hampshire Hospitals & Ain Shams University Hospitals, Basingstoke, UK
| | - Raj Nigam
- BMI Mount Alvernia Hospital, Guildford, Surrey, UK
| | - Raj Persad
- Department of Urology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK
| | - Jaspal Virdi
- Department of Urology, Princes Alexandra Hospital NHS Trust, Harlow, UK.,Rivers Hospital, Essex, UK
| | | | - Caroline Moore
- Department of Surgery and Interventional Sciences, University College London, and University College Hospital London, London, UK.,Department of Urology, UCLH NHS Foundation Trust, London, UK
| | - Clement Orczyk
- Department of Surgery and Interventional Sciences, University College London, and University College Hospital London, London, UK.,Department of Urology, UCLH NHS Foundation Trust, London, UK
| | - Mark Emberton
- Department of Surgery and Interventional Sciences, University College London, and University College Hospital London, London, UK.,Department of Urology, UCLH NHS Foundation Trust, London, UK
| | - Manit Arya
- Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.,Imperial Urology, Imperial College Healthcare NHS Trust, London, UK.,Department of Urology, Princes Alexandra Hospital NHS Trust, Harlow, UK.,Rivers Hospital, Essex, UK.,Department of Urology, UCLH NHS Foundation Trust, London, UK
| | - Hashim U Ahmed
- Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.,Imperial Urology, Imperial College Healthcare NHS Trust, London, UK
| | | | - Matt Winkler
- Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.,Imperial Urology, Imperial College Healthcare NHS Trust, London, UK
| | - Alison Falconer
- Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.,Imperial Urology, Imperial College Healthcare NHS Trust, London, UK
| |
Collapse
|
9
|
Abstract
PURPOSE OF REVIEW The goal of this study is to review recent findings and evaluate the utility of MRI transrectal ultrasound fusion biopsy (FBx) techniques and discuss future directions. RECENT FINDINGS FBx detects significantly higher rates of clinically significant prostate cancer (csPCa) than ultrasound-guided systematic prostate biopsy (SBx), particularly in repeat biopsy settings. FBx has also been shown to detect significantly lower rates of clinically insignificant prostate cancer. In addition, a dedicated prostate MRI can assist in more accurately predicting the Gleason score and provide further information regarding the index cancer location, prostate volume, and clinical stage. The ability to accurately evaluate specific lesions is vital to both focal therapy and active surveillance, for treatment selection, planning, and adequate follow-up. FBx has been demonstrated in multiple high-quality studies to have improved performance in diagnosis of csPCa compared to SBx. The combination of FBx with novel technologies including radiomics, prostate-specific membrane antigen positron emission tomography (PSMA PET), and high-resolution micro-ultrasound may have the potential to further enhance this performance.
Collapse
|
10
|
Carmona Echeverria LM, Haider A, Freeman A, Stopka-Farooqui U, Rosenfeld A, Simpson BS, Hu Y, Hawkes D, Pye H, Heavey S, Stavrinides V, Norris JM, Bosaily AES, Cardona Barrena C, Bott S, Brown L, Burns-Cox N, Dudderidge T, Henderson A, Hindley R, Kaplan R, Kirkham A, Oldroyd R, Ghei M, Persad R, Punwani S, Rosario D, Shergill I, Winkler M, Ahmed HU, Emberton M, Whitaker HC. A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. Sci Rep 2020; 10:17177. [PMID: 33057024 PMCID: PMC7561724 DOI: 10.1038/s41598-020-73524-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Accepted: 08/28/2020] [Indexed: 01/02/2023] Open
Abstract
Gleason score 7 prostate cancer with a higher proportion of pattern 4 (G4) has been linked to genomic heterogeneity and poorer patient outcome. The current assessment of G4 proportion uses estimation by a pathologist, with a higher proportion of G4 more likely to trigger additional imaging and treatment over active surveillance. This estimation method has been shown to have inter-observer variability. Fifteen patients with Prostate Grade Group (GG) 2 (Gleason 3 + 4) and fifteen patients with GG3 (Gleason 4 + 3) disease were selected from the PROMIS study with 192 haematoxylin and eosin-stained slides scanned. Two experienced uropathologists assessed the maximum cancer core length (MCCL) and G4 proportion using the current standard method (visual estimation) followed by detailed digital manual annotation of each G4 area and measurement of MCCL (planimetric estimation) using freely available software by the same two experts. We aimed to compare visual estimation of G4 and MCCL to a pathologist-driven digital measurement. We show that the visual and digital MCCL measurement differs up to 2 mm in 76.6% (23/30) with a high degree of agreement between the two measurements; Visual gave a median MCCL of 10 ± 2.70 mm (IQR 4, range 5–15 mm) compared to digital of 9.88 ± 3.09 mm (IQR 3.82, range 5.01–15.7 mm) (p = 0.64) The visual method for assessing G4 proportion over-estimates in all patients, compared to digital measurements [median 11.2% (IQR 38.75, range 4.7–17.9%) vs 30.4% (IQR 18.37, range 12.9–50.76%)]. The discordance was higher as the amount of G4 increased (Bias 18.71, CI 33.87–48.75, r 0.7, p < 0.0001). Further work on assessing actual G4 burden calibrated to clinical outcomes might lead to the use of differing G4 thresholds of significance if the visual estimation is used or by incorporating semi-automated methods for G4 burden measurement.
Collapse
Affiliation(s)
- Lina Maria Carmona Echeverria
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK. .,Division of Surgery and Interventional Science, Department of Urology, University College London Hospital, 235 Euston Road, London, NW1 2BU, UK.
| | - Aiman Haider
- Department of Pathology, University College London Hospital, 60 Whitfield Street, London, W1T4EU, UK
| | - Alex Freeman
- Department of Pathology, University College London Hospital, 60 Whitfield Street, London, W1T4EU, UK
| | - Urszula Stopka-Farooqui
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK
| | - Avi Rosenfeld
- Department of Computer Science, Jerusalem College of Technology, Havaad Haleumi 21, Givat Mordechai, 91160, Jerusalem, Israel
| | - Benjamin S Simpson
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK
| | - Yipeng Hu
- Centre for Medical Image Computing, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK
| | - David Hawkes
- Centre for Medical Image Computing, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK
| | - Hayley Pye
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK
| | - Susan Heavey
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK
| | - Vasilis Stavrinides
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK.,Division of Surgery and Interventional Science, Department of Urology, University College London Hospital, 235 Euston Road, London, NW1 2BU, UK
| | - Joseph M Norris
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK.,Division of Surgery and Interventional Science, Department of Urology, University College London Hospital, 235 Euston Road, London, NW1 2BU, UK
| | - Ahmed El-Shater Bosaily
- Division of Surgery and Interventional Science, Department of Urology, University College London Hospital, 235 Euston Road, London, NW1 2BU, UK.,Department of Radiology, Royal Free London NHS Foundation Trust, Pond Street, London, NW3 2QG, UK
| | - Cristina Cardona Barrena
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK
| | - Simon Bott
- Department Urology, Frimley Park Hospital, Frimley Health NHS Foundation Trust, Portsmouth Road, Camberley, Surrey, GU16 7UJ, UK
| | - Louise Brown
- MRC Clinical Trials Unit at UCL, 90 High Holborn, London, WC1V 6LJ, UK
| | - Nick Burns-Cox
- Department of Urology, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, TA1 5DA, UK
| | - Tim Dudderidge
- Department of Urology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, Hampshire, SO16 6YD, UK
| | - Alastair Henderson
- Department of Urology, Maidstone and Tunbridge Wells NHS Trust, Hermitage Lane, Tunbridge Wells, ME16 9QQ, UK
| | - Richard Hindley
- Department of Urology, Hampshire Hospitals NHS Foundation Trust, Aldermaston Road, Basingstoke, Hampshire, RG24 9NA, UK
| | - Richard Kaplan
- MRC Clinical Trials Unit at UCL, 90 High Holborn, London, WC1V 6LJ, UK
| | - Alex Kirkham
- Centre for Medical Image Computing, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK.,Department of Radiology, UCLH NHS Foundation Trust, University College London Hospital, 235 Euston Road, London, NW1 2BU, UK
| | - Robert Oldroyd
- Public and Patient Representative, 19 Exbury Gardens, West Bridgford, Nottingham, NG2 7SL, UK
| | - Maneesh Ghei
- Department of Urology, Whittington Health NHS Trust, Magdala Avenue, London, N19 5NF, UK
| | - Raj Persad
- Department of Urology, North Bristol NHS Trust, Southmead Road, Westbury-on-Trym, Bristol, BS10 5NB, UK
| | - Shonit Punwani
- Centre for Medical Image Computing, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK.,Department of Radiology, UCLH NHS Foundation Trust, University College London Hospital, 235 Euston Road, London, NW1 2BU, UK
| | - Derek Rosario
- Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Glossop Road, Sheffield, South Yorkshire, S10 2JF, UK
| | - Iqbal Shergill
- Department of Urology, Wrexham Maelor Hospital NHS Trust, Croesnewydd Road, Wrexham, LL13 7TD, UK
| | - Mathias Winkler
- Department of Urology, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| | - Hashim U Ahmed
- Department of Urology, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.,Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| | - Mark Emberton
- Division of Surgery and Interventional Science, Department of Urology, University College London Hospital, 235 Euston Road, London, NW1 2BU, UK
| | - Hayley C Whitaker
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK
| |
Collapse
|
11
|
Morselli S, Sebastianelli A, Campi R, Liaci A, Gabellini L, Tasso G, Fantechi R, Venturini S, Spatafora P, Cito G, Vignolini G, Raspollini MR, Gacci M, Serni S. Adverse pathology after radical prostatectomy: the prognostic role of cumulative cancer length >6-mm threshold in prostate cancer-positive biopsies. Prostate Int 2019; 7:143-149. [PMID: 31970139 PMCID: PMC6962732 DOI: 10.1016/j.prnil.2019.09.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 07/17/2019] [Accepted: 09/24/2019] [Indexed: 12/19/2022] Open
Abstract
Background To investigate the role of Cumulative Cancer Length (CCL) and PCa positive core number (PCapcn) in random prostate biopsies as predictors of Adverse Pathology (AP) at definitive pathology. Methods We prospectively enrolled patients submitted to random ultrasound guided prostate biopsies for suspect PCa in our center since 2016. Inclusion criteria were PSA <20 ng/ml or >3 ng/ml and age<71 years. Data on CCL and Grade Group (GG) at biopsy and pathology after Radical Prostatectomy (RP) were collected. AP was defined as pT3 or higher TNM, Positive Surgical Margin (>2mm) or PCa Positive Lymph Node. ROC curve was used to establish an appropriate CCL and PCapcn thresholds that were then investigated as predictors of AP at definitive pathology. Results Among 882 eligible biopsies, 344 had PCa and underwent RP. Mean age was 64 years (SD 5). Mean PSA was 7.75 (SD: 3.66). At definitive pathology there were AP features in 196 (56.9%) RP. PCapcn and CCL were statistically significantly associated with AP (p<0.0001). At multivariate age-adjusted logistic regression only PCapcn had an OR of 1.513 (CI95% 1.140-2.007) p=0.004. Through ROC curve a CCL>6mm and PCapcn >3 thresholds for AP were established (Area: 0.769; p<0.0001 CI 95% 0.698-0.840 and Area: 0.767; p<0.0001 CI 95% 0.696-0.837). When considering CCL>6mm AP had OR 5.462 (CI 95% 2.717-10.978) p<0.0001 and PCapcn >3 had OR 7.127 (CI 95% 3.366-15.090) p<0.0001. In particular, for GG 1 and 2, CCL>6mm had OR 3.989 (CI 95% 1.839-8.652) p<0.0001, while PCapcn >3 had OR 5.541 (CI 95% 2.390-12.849) p<0.0001. Conclusions At present time, random prostate biopsies might carry useful information regarding tumor extension and aggressiveness. A CCL>6mm or PCapcn >3 might be associated with AP features, in particular for low and favorable intermediate risk PCa.
Collapse
Affiliation(s)
- Simone Morselli
- Department of Urology, Careggi University Hospital, Florence, Italy
| | | | - Riccardo Campi
- Department of Urology, Careggi University Hospital, Florence, Italy
| | - Andrea Liaci
- Department of Urology, Careggi University Hospital, Florence, Italy
| | - Linda Gabellini
- Department of Urology, Careggi University Hospital, Florence, Italy
| | - Giovanni Tasso
- Department of Urology, Careggi University Hospital, Florence, Italy
| | | | | | - Pietro Spatafora
- Department of Urology, Careggi University Hospital, Florence, Italy
| | - Gianmartin Cito
- Department of Urology, Careggi University Hospital, Florence, Italy
| | | | | | - Mauro Gacci
- Department of Urology, Careggi University Hospital, Florence, Italy
| | - Sergio Serni
- Department of Urology, Careggi University Hospital, Florence, Italy
| |
Collapse
|